Merck announced today that the FDA approved JANUVIA™ (sitagliptin phosphate), the first DPP-4 inhibitor available in the United States for the treatment of type 2 diabetes.
Januvia has been approved as monotherapy and as add-on therapy to either of two other types of oral diabetes medications, metformin or thiazolidinediones (TZDs), to improve blood sugar (glucose) control in patients with type 2 diabetes when diet and exercise is not enough.
The recommended dose of Januvia is 100 mg once daily. Januvia should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis, as it would not be effective in these settings.
No comments:
Post a Comment